Genentech is aiming to lead the charge for clinical trial diversity in the pharma industry and it’s using a mix of regulatory commitments, trial site partnerships and community activism to get there.
Genentech has already filed 20 diversity action plans for Phase 3 studies with the FDA ahead of the…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
